-
Series: Risk InsightsLiquid Biopsy and the Early Diagnosis of Cancer
Issue: Nov 02, 2020 Critical Illness English
In recent years, the primary tool for early diagnosis of cancer has been liquid biopsy (a blood test), but it remains complex, costly and time-consuming to fully screen for all mutations.
Read More -
Changes in Cancer Classification - How Do They Impact Critical Illness Insurance?
By Tim Eppert Jul 14, 2020 English Français
What is a cancer - and what is not? While the answer to this question is obvious in many cases, it is not always straightforward. A disease is deemed as malignant or cancerous when there is an uncontrolled growth of cells that is invasive, i.e., the cells...
Read More -
CEA Screening - Useful in Life & Health Underwriting?
By Dr. Thomas Ashley Mar 26, 2020 English Français
Some insurers have added the carcinoembryonic antigen (CEA) blood test to the laboratory screening profile for Life and Health insurance applications, and some of our U.S. clients have asked for advice on whether to adopt this test. Every test has repercussions...
Read More -
World Cancer Day - Celebrating a Decline in U.S. Cancer Mortality
By Jean-Marc Fix Feb 04, 2020 English
When the Cancer Statistics, 2020 report was released a few weeks ago, the press rightfully basked in the great news: In the U.S. there were 2.9 million fewer cancer deaths than there would have been if the historically increasing cancer rates had remained...
Read More
